Research
Bulevirtide Linked to Less Decompensation in Chronic Hep D With Cirrhosis
The Brief
- In patients with chronic hepatitis delta and cirrhosis, bulevirtide (Hepcludex) treatment was associated with a lower risk of liver decompensation.
- The findings come from a European retrospective study, as reported by MedPage Today from the AASLD meeting coverage.
Why it matters
Liver decompensation is a major complication of cirrhosis, so an association between bulevirtide and fewer decompensation events is relevant to how clinicians manage this patient group. Because the study is retrospective, it shows an association rather than proof of causation.
Who’s affected
- hepatologists and clinicians treating chronic hepatitis delta
- patients with chronic hepatitis delta and cirrhosis
- #hepatitis delta
- #bulevirtide
- #cirrhosis
- #liver decompensation
- #hepatology
(MedPage Today) -- In patients with chronic hepatitis delta (CHD) with cirrhosis, treatment with bulevirtide (Hepcludex) was associated with lower risk of liver decompensation, according to results from a European retrospective study. Among more...